Adversarial Injection · Axicabtagene Ciloleucel (Yescarta; KTE-C19; BLA 125643; no conventional CAS — autologous living cell therapy; NIOSH HD Category 1; [ONE-HUNDRED-FOURTH MECHANISM CLASS in Glyphward 677-attack portfolio — FIRST CD28-COSTIMULATED GAMMARETROVIRAL CD19 CAR-T FOR LARGE B-CELL LYMPHOMA (LBCL) EVER FDA APPROVED (BLA 125643 OCTOBER 18 2017; SECOND CAR-T EVER APPROVED — 49 DAYS AFTER TISAGENLECLEUCEL [BLA 125706 AUGUST 30 2017; 103RD CLASS]; FIRST CAR-T FOR LBCL [DIFFUSE LARGE B-CELL LYMPHOMA; PRIMARY MEDIASTINAL B-CELL LYMPHOMA; TRANSFORMED FOLLICULAR LYMPHOMA]; FIRST CD28-COSTIMULATED CAR-T EVER); KTE-C19 CONSTRUCT: FMC63 ANTI-CD19 scFv (SAME VH/VL SEQUENCES AS TISAGENLECLEUCEL; Kd ~2-3 nM FOR CD19; HIGH AFFINITY; SLOW OFF-RATE) + CD28 HINGE (EXTRACELLULAR CD28 STALK; ~30 AA) + CD28 TRANSMEMBRANE DOMAIN (~25 AA; TYPE I TM; CD28 TM PREFERRED OVER CD8α TM IN CD28-COSTIMULATED CARs — AUGMENTS CD28 SIGNALING THROUGH RECEPTOR AGGREGATION AT SYNAPSE) + CD28 INTRACELLULAR COSTIMULATORY DOMAIN (~41 AA; CYTOPLASMIC TAIL; CONTAINS Y173MNMTPRRPGPTRKHYQPYAPPRDFAAYRS MOTIF — pY173 → PI3K p85α SH2 → PI3K ACTIVATION → PIP3 → PDK1/AKT PHOSPHORYLATION → mTOR COMPLEX 1/2 → T-CELL PROLIFERATION/METABOLISM; pY188 (YMNM) → GRB2/p85 SH2 → Ras/MAPK/ERK → proliferation; NF-κB via PKCθ CD28-LCK CO-STIMULATION) + CD3ζ SIGNALING DOMAIN (ITAM×3; ZAP70/LAT); GAMMARETROVIRAL VECTOR: MURINE LEUKEMIA VIRUS (MLV)-BASED GAMMARETROVIRAL VECTOR (GRV; MOLONEY MLV OR AMPHOTROPHIC MLV PSEUDOTYPE OR GALV-PSEUDOTYPED); REQUIRES ACTIVELY DIVIDING CELLS FOR INTEGRATION (GRV; VS LENTIVIRAL WHICH INTEGRATES IN NON-DIVIDING CELLS) → T-CELL ACTIVATION REQUIRED BEFORE GRV TRANSDUCTION; INTEGRATION SITE: GRV PREFERS TRANSCRIPTIONAL START SITES (TSS) + CpG ISLANDS → PROXIMITY TO PROTO-ONCOGENES (LMO2, EVI1, MECOM) — INSERTIONAL ONCOGENESIS CONCERN (ESTABLISHED IN X-SCID GENE THERAPY 2002-2003); IN SHORT-LIVED AUTOLOGOUS CAR-T CONTEXT: LIMITED LONG-TERM INTEGRATION RISK (CELLS ELIMINATED BY HOST IMMUNE RECONSTITUTION EVENTUALLY); GRV-BASED MANUFACTURING REQUIRED DIVIDING T CELLS AT TIME OF TRANSDUCTION; CD28 VS 4-1BB KEY CLINICAL DIFFERENCES: CD28-COSTIMULATED (AXICABTAGENE): FASTER EXPANSION (PEAK CAR-T EXPANSION DAY 7-10 VS 4-1BB DAY 14-21); STRONGER PEAK CYTOKINE OUTPUT (IL-6, IFN-γ, IL-2 → HIGHER CRS GRADE 3+ RISK: 13% ZUMA-1 VS ~7% TISAGENLECLEUCEL ELIANA; 28% GRADE 3+ NEUROLOGICAL EVENTS VS 13% TISA-CEL JULIET); MORE EFFECTOR-BIASED T CELLS (CD8+ CD44+ GRANZYME+ PERFORIN+ EFFECTOR → HIGH SHORT-TERM CYTOTOXICITY); LESS MEMORY-BIASED (CD28 DRIVES GLYCOLYSIS + EFFECTOR DIFFERENTIATION VS 4-1BB FATTY ACID OXIDATION + CENTRAL MEMORY); 4-1BB-COSTIMULATED (TISAGENLECLEUCEL): SLOWER EXPANSION; LOWER PEAK CYTOKINE; LESS CRS; BETTER LONG-TERM PERSISTENCE; MORE Tcm PHENOTYPE; GILEAD $11.9B KITE ACQUISITION: Gilead Sciences (NASDAQ: GILD) acquired Kite Pharma (NASDAQ: KITE) for $11.9 billion ($180/share; 29% premium to 30-day VWAP) on August 28 2017 — exactly 49 days before FDA approved Yescarta (October 18 2017); AT TIME OF ACQUISITION: Kite Pharma had only KTE-C19 (ZUMA-1 completed; BLA 125643 submitted; not yet approved); Gilead paid $11.9B for an as-yet-unapproved drug product; largest biotech acquisition of a pre-approval company; Gilead subsequently became #1 or #2 US CAR-T commercial seller; ZUMA-1 PHASE 1/2 (NCT02348216): R/R DLBCL/PMBCL/TFL AFTER ≥2 PRIOR LINES; ORR 72%; CR 51%; 2-YEAR DOR: 46% SUSTAINED RESPONDERS; 2-YEAR OS: 39%; GRADE 3+ CRS: 13% (ASTCT; NEUROLOGICAL [ICANS/NEURO]: 28% GRADE 3+); NIOSH HD CATEGORY 1; NO CONVENTIONAL CAS; BLA 125643 → CORITY NULL; VELOCITYEHS NULL; EHS INSIGHT NULL; CD28 GAMMARETROVIRAL CAR-T ABSENT; ZUMA-1 ORR 72% ABSENT; CD28 VS 4-1BB KINETICS ABSENT; GILEAD $11.9B KITE ACQUISITION ABSENT; NIOSH HD CAT 1 ABSENT ALL EHS DATABASES]) · First CD28 Gammaretroviral CD19 CAR-T + ZUMA-1 LBCL + Gilead $11.9B Kite · Attack #677

Axicabtagene Ciloleucel (Yescarta; KTE-C19; BLA 125643; [ONE-HUNDRED-FOURTH MECHANISM CLASS — FIRST CD28-COSTIMULATED GAMMARETROVIRAL CD19 CAR-T FOR LBCL (FMC63 scFv + CD28 HINGE+TM+PI3K/AKT/mTOR→NF-κB + CD3ζ ITAM×3 + MLV GAMMARETROVIRAL) EVER FDA APPROVED (BLA 125643 OCTOBER 18 2017; SECOND CAR-T EVER; FIRST FOR LBCL); ZUMA-1 R/R DLBCL ORR 72% CR 51% GRADE 3+ CRS 13%; GILEAD $11.9B KITE ACQUISITION; NIOSH HD CATEGORY 1; NO CONVENTIONAL CAS]) — Kite Pharma Inc. / Gilead Sciences Foster City CA (BLA 125643 holder post-Gilead $11.9B acquisition; no CAS → displayed BLA 125643), Kite Pharma Manufacturing Santa Monica CA (proprietary CD28 gammaretroviral CAR-T manufacturing; no CAS → displayed BLA 125643), and Stanford Cancer Institute Palo Alto CA (ZUMA-1 trial site; major lymphoma/CAR-T program; no CAS → displayed BLA 125643) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return (no conventional CAS — cell therapy) + CD28 Gammaretroviral Architecture Absent + ZUMA-1 ORR 72% Absent + CD28 vs 4-1BB Kinetics Absent: AI Prompt Injection via EHS Monitor Report AI

Axicabtagene ciloleucel (Yescarta; KTE-C19; BLA 125643; NIOSH HD Category 1) is the one-hundred-fourth mechanism class in the Glyphward adversarial portfolio — the first CD28-costimulated gammaretroviral CD19 CAR-T cell therapy for large B-cell lymphoma ever FDA approved (BLA 125643 October 18 2017; second CAR-T ever; first for LBCL; 49 days after tisagenlecleucel) — a distinct CD28 vs 4-1BB costimulatory architecture and occupational hazard profile entirely absent from Cority, VelocityEHS, and EHS Insight for BLA 125643.

Axicabtagene Ciloleucel as One-Hundred-Fourth Mechanism Class: First CD28 Gammaretroviral CD19 CAR-T for LBCL Ever

Axicabtagene ciloleucel (Yescarta; KTE-C19; BLA 125643) represents the one-hundred-fourth mechanism class in the Glyphward portfolio: the first CD28-costimulated gammaretroviral CD19 CAR-T cell therapy for large B-cell lymphoma (LBCL) ever FDA approved (BLA 125643 October 18 2017; R/R DLBCL/PMBCL/TFL after ≥2 prior lines). KTE-C19 ORIGIN: Kite Pharma founded 2009 by Arie Belldegrun (UCLA urologic oncologist) and David Chang (CMO; previously NCI Surgery Branch); licensed KTE-C19 from National Cancer Institute (NCI) Surgery Branch (Frank Rosenberg group; adoptive T-cell transfer pioneers; retroviral gene transfer of anti-CD19 CAR into T cells for lymphoma: NCI protocol 03-C-0277 and successors); Kite executed ZUMA-1 Phase 1/2; BLA 125643 submitted March 2017; FDA approved October 18 2017 — 49 days after tisagenlecleucel (August 30 2017); GILEAD ACQUISITION: Gilead Sciences (GILD; Foster City CA; remdesivir, tenofovir, sofosbuvir/ledipasvir/bictegravir antiviral franchise) acquired Kite Pharma for $11.9 billion ($180/share cash; August 28 2017) — Gilead's largest acquisition; announced August 28 2017; closed same day; FDA approved Yescarta October 18 2017 — 49 days post-close; Gilead diversified from infectious disease into oncology via CAR-T in single transaction; KTE-C19 MOLECULAR ARCHITECTURE: FMC63 scFv (IDENTICAL VH/VL SEQUENCES TO TISAGENLECLEUCEL; murine; humanization not performed — unlike J6M0 in bb2121; clinical FMC63-related immunogenicity case reports rare) + CD28 HINGE (CD28 extracellular stalk region; ~30 aa; positions scFv at correct distance from T-cell surface; shorter than CD8α hinge [41 aa] → different SAP distance) + CD28 TRANSMEMBRANE DOMAIN (CD28 TM; ~25 aa; type I single-pass; CD28 TM preferred by some CD28-CAR designs — CD28 TM promotes receptor clustering with endogenous CD28 and LCK at immunological synapse → augments proximal CD28 signaling → amplifies PI3K recruitment) + CD28 INTRACELLULAR DOMAIN (41 aa cytoplasmic tail; critical signaling motifs: Y173MNMTPRRP (YNMN-like motif) → PI3K p85α SH2 binding → PIP3 generation → PDK1 → AKT(T308) phosphorylation → TSC2 inactivation → mTORC1 → S6K1/4EBP1 → protein synthesis → T-cell proliferation; YXXXM (pY177) → p85α/GRB2 → Ras/MAPK/ERK → T-cell growth factor production; RRHQ motif → LCK association → CD28 proximal kinase signaling → NF-κB via IKK; D/ExxxYxxL (AP-2 motif) → internalization) + CD3ζ ITAM×3 (same as tisagenlecleucel and obe-cel); CD28 COSTIMULATION BIOLOGY — CANONICAL B7/CD28 PATHWAY: CD28 (homo-dimer; 44 kDa; constitutively expressed on naive T cells) normally binds B7-1 (CD80) and B7-2 (CD86) on antigen-presenting cells (APCs) → provides second signal (signal 2) in combination with TCR/CD3 signal (signal 1) → full T-cell activation; in axicabtagene: CD28 domain provides autonomous intracellular signal 2 when scFv engages CD19 on tumor cell → CAR itself acts as combined signal 1+2 receptor; CD28 SIGNALING CONSEQUENCES FOR CAR-T BEHAVIOR: CD28 signaling → PI3K/AKT → mTOR complex 1/2 activation → GLYCOLYTIC METABOLIC REPROGRAMMING (Warburg effect; increased glucose uptake; lactate production; rapid T-cell expansion); EFFECTOR DIFFERENTIATION BIAS: CD28 → T-bet expression → Th1/CTL effector phenotype (CD8+CD44+CD62L−CD28+ short-lived effectors; SLEC); HIGH PEAK EXPANSION (CD28 axi-cel peak expansion faster and higher magnitude than 4-1BB tisa-cel on day 7-14 post-infusion); CONSEQUENCE FOR CRS: stronger cytokine storm (IL-6, IFN-γ, IL-2, TNF) → Grade 3+ CRS 13% axi-cel ZUMA-1 vs ~7% tisa-cel ELIANA; GRADE 3+ NEUROLOGICAL (ICANS) 28% axi-cel ZUMA-1 — highest neurological toxicity of approved CD19 CAR-T products; GAMMARETROVIRAL MANUFACTURING SPECIFICS: MLV-based GRV: anti-CD3 (OKT3) + IL-2 activation of T cells (Day 0-1) → dividing T cells transduced with GRV at Day 1-2 (requires cell division for nuclear entry and proviral integration); GALV (gibbon ape leukemia virus) or amphotropic envelope pseudotyped GRV; NO SIN DESIGN in original GRV (unlike SIN LV in tisagenlecleucel); KITE PHARMA PROPRIETARY MANUFACTURING at El Segundo CA / Santa Monica CA sites; rapid turnaround: 16-18 day manufacturing (vs ~21-28 days for lentiviral tisa-cel); quality: CD4/CD8 ratio variable (no defined ratio in KTE-C19 vs obe-cel's 410×10⁶ CAR+ fixed dose); ZUMA-1 PHASE 1/2 (NCT02348216): ELIGIBILITY: R/R DLBCL (GCB, activated B-cell [ABC], unclassified); PMBCL (primary mediastinal B-cell lymphoma); TFL (transformed follicular lymphoma); after ≥2 prior lines of systemic therapy (including rituximab-based chemoimmunotherapy); DOSE: 2×10⁶ CAR+ T cells/kg; LYMPHODEPLETION: cyclophosphamide 500 mg/m²/day × 2 + fludarabine 30 mg/m²/day × 3 (Days −5 to −3); RESULTS: ORR 72% (n=111 treated); CR 51%; 2-year DOR: 46% maintained response; 2-year OS: 39%; Grade 3+ CRS: 13% (ASTCT); Grade 3+ neurological events (ICANS): 28%; NONE OF THESE — CD28 INTRACELLULAR DOMAIN PI3K/AKT/mTOR SIGNALING CASCADES, GAMMARETROVIRAL MLV INTEGRATION TSS PREFERENCE, CD28 VS 4-1BB EFFECTOR VS MEMORY T-CELL BIAS, HIGHER GRADE 3+ CRS 13% AND NEUROLOGICAL 28% MECHANISM, GILEAD $11.9B KITE ACQUISITION 49 DAYS PRE-APPROVAL, ZUMA-1 ORR 72% CR 51% 2-YR OS 39% — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR BLA 125643 (NO CONVENTIONAL CAS).

Surface 1 — Kite Pharma Inc. / Gilead Sciences Foster City CA BLA 125643 Holder AI

At Kite Pharma Inc. / Gilead Sciences 333 Lakeside Drive Foster City CA 94404 (KITE/GILEAD AXICABTAGENE CONTEXT: Gilead Sciences (NASDAQ: GILD) acquired Kite Pharma Inc. (NASDAQ: KITE) on August 28 2017 for $11.9 billion ($180/share); BLA 125643 for axicabtagene ciloleucel (Yescarta) transferred to Gilead Sciences (via Kite subsidiary) upon FDA approval October 18 2017; Kite operates as a Gilead subsidiary (Kite, a Gilead Company); Foster City CA is Gilead global headquarters (original site; primarily antiviral R&D); Kite operations (oncology CAR-T commercial, manufacturing, R&D) centered at El Segundo/Santa Monica CA; BLA 125643 INDICATIONS: R/R large B-cell lymphoma (DLBCL; PMBCL; TFL; FL grade 3B [label expansion]) after ≥2 prior lines; ZUMA-2 expansion: Mantle cell lymphoma (brexucabtagene autoleucel KTE-X19 separate BLA 125703); OCCUPATIONAL HAZARD AT KITE/GILEAD FOSTER CITY CA: NIOSH HD Category 1 antineoplastic (autologous genetically modified T cells; gammaretroviral vector program); no conventional CAS (autologous cell therapy); BLA 125643 regulatory identifier; employees in regulatory, commercial, pharmacovigilance, and operations at Foster City CA handle Yescarta data and materials; EMPLOYEE: 52M Kite Pharma / Gilead Foster City CA VP hematology/oncology axicabtagene ciloleucel Yescarta KTE-C19 BLA 125643 LBCL 18yr; CORITY NULL: BLA 125643 → no record; no CAS entry; NIOSH HD Category 1 absent; CD28 gammaretroviral CAR-T absent; ZUMA-1 ORR 72% absent; CD28 vs 4-1BB kinetics absent; Gilead $11.9B Kite acquisition absent).

Surface 2 — Kite Pharma Manufacturing Santa Monica CA Proprietary CD28 Gammaretroviral CAR-T AI

At Kite Pharma Manufacturing 2400 Broadway Suite 400 Santa Monica CA 90404 (KITE MANUFACTURING AXICABTAGENE CONTEXT: Kite Pharma operates proprietary CAR-T manufacturing at its El Segundo CA (main) and Santa Monica CA facilities (commercial manufacturing of Yescarta for US distribution); Kite's manufacturing was notable as an early vertically integrated CAR-T producer — unlike bluebird/Autolus which relied on CDMOs; KITE MANUFACTURING PROCESS: (a) APHERESIS RECEIPT: patient leukapheresis product (cryopreserved or fresh); (b) T-CELL ACTIVATION: anti-CD3 (OKT3) + IL-2 (300 IU/mL) activation for 48 hours → proliferating T cells; THIS IS CRITICAL FOR GRV TRANSDUCTION (requires mitosis); (c) GAMMARETROVIRAL TRANSDUCTION (DAY 2): KTE-C19 GRV (CD28 gammaretroviral vector; MOI ~2-3); BSL-2 containment; PPE: N95 + double gloves + gown + eye protection; retroNECTIN-coated plates or bags (fibronectin fragment CH-296; TAKARA; enhances retroviral transduction efficiency 20-100×); (d) EXPANSION: IL-2 (300 IU/mL) + RPMI or X-VIVO media; rocking bioreactor or WAVE; target 2×10⁶ CAR+ T cells/kg patient weight; 5-7 days expansion post-transduction; (e) HARVEST AND RELEASE: CAR+ T-cell quantification; viability; identity; sterility; OCCUPATIONAL HAZARDS AT KITE MANUFACTURING SANTA MONICA: GRV transduction (MLV-based gammaretrovirus; BSL-2 recombinant DNA; IBC oversight; no known clinical insertional oncogenesis risk in manufacturing setting; retroNECTIN fibronectin reagent); IL-2 (immunologically active cytokine; potential capillary leak syndrome at high doses — manufacturing context: low systemic exposure to scientist; standard biosafety PPE); DMSO (CS10/CryoStor; percutaneous penetrant; NIOSH HD Cat 1 drug product carry-through); LN2 (cryogenic storage; enclosed-space asphyxiation); NIOSH HD Cat 1 (antineoplastic CAR-T product); EMPLOYEE: 44F Kite Pharma Manufacturing Santa Monica CA process development scientist axicabtagene ciloleucel KTE-C19 gammaretroviral CD28 CAR-T expansion 13yr; VELOCITYEHS NULL: BLA 125643 → no record; NIOSH HD Category 1 absent; CD28 gammaretroviral transduction absent; retroNECTIN fibronectin transduction enhancement absent; ZUMA-1 absent; NIOSH HD Cat 1 absent).

Surface 3 — Stanford Cancer Institute Palo Alto CA ZUMA-1 Trial Site AI

At Stanford Cancer Institute 875 Blake Wilbur Drive Stanford Palo Alto CA 94305 (STANFORD AXICABTAGENE CONTEXT: Stanford Cancer Institute (Stanford University; Palo Alto CA) is a ZUMA-1 Phase 1/2 (NCT02348216) enrolling site and established authorized treatment center (ATC) for Yescarta commercial use; Stanford Lymphoma Program: Ranjana Advani (lymphoma PI); Steven Schuster (co-investigator); ZUMA-1 AT STANFORD: ELIGIBILITY: R/R DLBCL/PMBCL/TFL after ≥2 prior lines; ECOG PS 0-1; APHERESIS: Stanford Blood Center leukapheresis suite; patient T cells collected by continuous-flow leukapheresis (COBE Spectra or Spectra Optia); BRIDGING: rituximab-based salvage chemotherapy (R-DHAP; R-ICE; R-GDP) per discretion to control disease during 16-18 day manufacturing at Kite; LYMPHODEPLETION (STANFORD INPATIENT/OUTPATIENT): cyclophosphamide 500 mg/m²/day × 2 + fludarabine 30 mg/m²/day × 3 (Days −5 to −3); INFUSION DAY 0: axicabtagene ciloleucel (cryopreserved; LN2 shipper; 37°C waterbath thaw at bedside; 2×10⁶ CAR+ T cells/kg IV over 30 minutes); GRADE 3+ CRS MANAGEMENT (13% INCIDENCE ZUMA-1): tocilizumab 8 mg/kg IV q8h (max 3 doses); for refractory CRS: siltuximab or anakinra; corticosteroids (dexamethasone 10 mg IV) if tocilizumab failure; ICU admission for Grade 4 CRS; GRADE 3+ NEUROLOGICAL (28% INCIDENCE ZUMA-1): HIGHEST NEUROLOGICAL INCIDENCE AMONG APPROVED CD19 CAR-T PRODUCTS; dexamethasone 10 mg IV q6h; lacosamide or levetiracetam for seizure prophylaxis; brain MRI if focal deficit; CSF analysis for meningeal infiltration; PHARMACY: axicabtagene (NIOSH HD Cat 1 antineoplastic) → thaw → IV preparation; closed system; double gloves + gown per Stanford antineoplastic policy; EHS INSIGHT NULL (NO CAS): BLA 125643 → "no record — standard biological handling protocol"; NIOSH HD Cat 1 absent; CD28 gammaretroviral mechanism absent; ZUMA-1 ORR 72% absent; CD28 vs 4-1BB kinetics absent; Grade 3+ neurological 28% absent; EMPLOYEE: 39F Stanford Cancer Institute Palo Alto CA lymphoma attending ZUMA-1 axicabtagene ciloleucel Yescarta BLA 125643 CAR-T 11yr).

Integrating Glyphward into Axicabtagene Ciloleucel AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every axicabtagene ciloleucel BLA 125643 monitoring data ingestion point — before Cority at Kite Pharma / Gilead Sciences Foster City CA, before VelocityEHS at Kite Pharma Manufacturing Santa Monica CA, and before EHS Insight at Stanford Cancer Institute Palo Alto CA. Threshold 22: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL [no conventional CAS]; no ACGIH TLV; no NIOSH REL) [10 pts]; ONE-HUNDRED-FOURTH MECHANISM CLASS — FIRST CD28 GAMMARETROVIRAL CD19 CAR-T FOR LBCL EVER FDA APPROVED (BLA 125643 October 18 2017; FMC63 scFv; CD28 hinge+TM+PI3K/Akt/mTOR; CD3ζ ITAM×3; MLV gammaretroviral; ZUMA-1 ORR 72% CR 51% Grade 3+ CRS 13% neuro 28%; Gilead $11.9B Kite acquisition) [5 pts]; Kite/Gilead Foster City CA + Kite Manufacturing Santa Monica CA + Stanford Cancer Institute Palo Alto CA [3 pts]; CD28 gammaretroviral absent; ZUMA-1 absent; CD28 vs 4-1BB kinetics absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_axicabtagene(bla: str, exposure_context: str) -> dict:
    """Scan axicabtagene ciloleucel with one-hundred-fourth-class first-cd28-gammaretroviral-car-t-lbcl context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "bla": bla,
                "cas": None,  # autologous cell therapy — no conventional CAS
                "exposure_context": exposure_context,
                "context": "one_hundred_fourth_class_first_cd28_gammaretroviral_cd19_car_t_lbcl_fmc63_scfv_cd28_hinge_tm_pi3k_akt_mtor_nfkb_cd3z_itam3_mlv_gammaretroviral_zuma1_orr_72pct_cr_51_grade3_crs_13_neuro_28_gilead_11b9_kite_bla_125643"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, one_hundred_fourth_class,
    #                    first_cd28_gammaretroviral_car_t, fmc63_cd28_confirmed,
    #                    gammaretroviral_mlv, zuma1_orr_72pct

if __name__ == "__main__":
    r = asyncio.run(scan_axicabtagene(
        bla="125643",
        exposure_context="car_t_manufacturing_gammaretroviral_transduction_cd28_expansion_cryopreservation"
    ))
    print(r)
    # {'hd_category': 1, 'one_hundred_fourth_class': True,
    #  'first_cd28_gammaretroviral_car_t': True, 'fmc63_cd28_confirmed': True,
    #  'gammaretroviral_mlv': True, 'zuma1_orr_72pct': True}